Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Linezolid is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the 70S initiation complex.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Treatment of vancomycin-resistant Enterococcus faecium infections including bacteremia,Treatment of nosocomial pneumonia caused by Staphylococcus aureus or Streptococcus pneumoniae,Treatment of complicated skin and skin structure infections including diabetic foot infections,Treatment of uncomplicated skin and skin structure infections,Treatment of community-acquired pneumonia,Off-label: Treatment of Nocardia infections, tuberculosis as part of combination therapy, and prosthetic joint infections
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
600 mg IV every 12 hours for 10-14 days.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life is approximately 5.5 hours; in patients with severe renal impairment (Cr Cl <30 m L/min), half-life may be prolonged to 7-8 hours.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Linezolid is primarily metabolized by oxidation of the morpholine ring to form two inactive metabolites: aminoethoxyacetic acid and hydroxyethyl glycine. The exact enzyme system is not fully characterized, but it is believed to be non-enzymatic or via minor cytochrome P450 pathways.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal excretion accounts for approximately 30% of the dose as unchanged drug; nonrenal clearance (likely hepatic metabolism) accounts for about 70%. Fecal excretion is minimal (<2%).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Approximately 31% bound to plasma proteins, primarily albumin (about 29%) and alpha-1-acid glycoprotein (about 10%).
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Steady-state volume of distribution is approximately 0.7 L/kg, indicating extensive distribution into well-perfused tissues (e.g., lungs, skin, muscle, and bone).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral bioavailability is approximately 100%, with a 600 mg oral tablet yielding AUC equivalent to a 30-minute IV infusion of 600 mg.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No dose adjustment required for any degree of renal impairment. However, the two primary metabolites may accumulate in severe renal impairment, but clinical significance is unknown.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No dose adjustment required for mild-to-moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe hepatic impairment (Child-Pugh C); use with caution.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Neonates and children <12 years: 10 mg/kg IV every 8 hours for 10-14 days. Children ≥12 years: same as adult dosing.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
No specific dose adjustment based on age alone. Monitor renal function as clearance may decrease with age, but no dose change recommended.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Linezolid is not approved for the treatment of catheter-related bloodstream infections or catheter-site infections. An increased risk of mortality was seen in patients with catheter-related bloodstream infections in a clinical trial.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Myelosuppression including anemia, leukopenia, thrombocytopenia, and pancytopenia,Peripheral and optic neuropathy,Lactic acidosis,Serotonin syndrome when coadministered with serotonergic agents,Convulsions,Clostridium difficile-associated diarrhea,Hypoglycemia in diabetic patients,Development of drug-resistant bacteria,Use in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or hyperthyroidism due to tyramine interactions
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Known hypersensitivity to linezolid or any component of the formulation,Concomitant use within 2 weeks of monoamine oxidase inhibitors (MAOIs)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid tyramine-containing foods and beverages to reduce risk of hypertensive crisis. Examples: aged cheeses (cheddar, blue cheese), cured/smoked meats (pepperoni, salami), fermented foods (sauerkraut, kimchi), soy products (tofu, miso), tap beers, red wines (Chianti), and overripe fruits (avocado, bananas). Patients should adhere to a low-tyramine diet during therapy and for 2 weeks after discontinuation.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Linezolid is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetal toxicity (reduced fetal weights, increased incidence of rib and vertebral anomalies) at doses approximately equivalent to the maximum human exposure. There are no adequate and well-controlled studies in pregnant women. In the first trimester, use only if potential benefit justifies potential risk to the fetus. In the second and third trimesters, limited data suggest no increased risk of major malformations, but potential for fetal effects due to maternal toxicity exists.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Linezolid is excreted in human milk. The milk-to-plasma (M/P) ratio is approximately 0.8. The estimated infant dose is about 1.3-1.4 mg/kg/day, which is less than 5% of the maternal therapeutic dose. However, due to potential for adverse effects (e.g., myelosuppression, peripheral neuropathy), caution is advised. Breastfeeding is not recommended during therapy and for 2-3 half-lives (approximately 12-18 hours) after the last dose.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Physiologic changes in pregnancy (increased volume of distribution, increased renal clearance) may affect linezolid pharmacokinetics. However, no formal dose adjustment studies in pregnancy. Standard adult dosing (600 mg IV or PO every 12 hours) is generally used. Consider monitoring serum levels (therapeutic trough 2-8 mcg/m L) if available, especially in severe infections. Dose adjustments may be necessary based on renal function (creatinine clearance <30 m L/min) but pregnancy-specific adjustments not established.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Linezolid is a reversible nonselective monoamine oxidase inhibitor (MAOI). Avoid concomitant use with serotonergic agents (e.g., SSRIs, SNRIs, triptans) due to risk of serotonin syndrome. Monitor for myelosuppression (especially thrombocytopenia) with prolonged therapy; complete blood counts should be checked weekly. Use with caution in uncontrolled hypertension, pheochromocytoma, or carcinoid syndrome due to potential for pressor response. Linezolid exhibits 100% oral bioavailability; intravenous form is used when oral route is not feasible.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Avoid tyramine-rich foods and beverages (e.g., aged cheeses, cured meats, fermented products, tap beers, red wine) to prevent hypertensive crisis.,Report any signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle twitching) or bleeding (easy bruising, petechiae).,Take exactly as prescribed; do not stop without consulting your doctor even if you feel better.,Inform all healthcare providers that you are taking linezolid, especially before surgery or receiving any new medications.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Procaterol, a beta-2 adrenergic agonist, may enhance the hypertensive effects of linezolid, an oxazolidinone antibiotic that acts as a weak, reversible monoamine oxidase inhibitor (MAOI). This additive effect on blood pressure results from increased sympathetic tone, potentially leading to hypertensive crises. Patients may experience elevated systolic and diastolic blood pressure, tachycardia, and in severe cases, hypertensive urgency or emergency, especially when systemic absorption occurs from inhaled procaterol."
"Linezolid is a reversible, nonselective monoamine oxidase inhibitor (MAOI) that inhibits the metabolism of sympathomimetic amines such as phenylpropanolamine. This leads to increased concentrations of phenylpropanolamine and enhanced adrenergic stimulation, resulting in elevated blood pressure and risk of hypertensive crisis. Clinically, patients may experience severe hypertension, tachycardia, headache, and potential end-organ damage."
"Desipramine, a tricyclic antidepressant, inhibits the reuptake of serotonin and norepinephrine, increasing their synaptic concentrations. Linezolid, an oxazolidinone antibiotic, is a reversible, nonselective monoamine oxidase inhibitor (MAOI). Co-administration can lead to excessive serotonergic activity, potentially causing serotonin syndrome, a life-threatening condition characterized by agitation, hyperthermia, autonomic instability, neuromuscular rigidity, and altered mental status."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Linezolid is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the 70S initiation complex.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 600 mg IV every 12 hours for 10-14 days.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Linezolid is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetal toxicity (reduced fetal weights, increased incidence of rib and vertebral an. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.